A recent visit from Zhou Xiaoming, Minister Counsellor from the Chinese Embassy, has capped a remarkable year for Innova Biosciences, a leader in bioconjugation and antibody labelling. Mr Xiaoming was in Cambridge looking at inward investment opportunities, which took in a tour of Innova’s new state-of-the-art facilities in Cambridge. The visit follows Innova’s appointment of two new distributors to sell its pioneering Lightning- Link antibody kit into China after support from UK Trade and Investment.
“We were delighted to welcome Mr Xiaoming,” said Innova Biosciences’ CEO, Dr Nick Gee. “The Minister was very interested in the work we are doing here and greatly impressed by our achievements — particularly our new relationship with the Chinese market. His visit has been the culmination of many years’ hard work by all the staff at Innova, during which we’ve become renowned for our antibody labeling kits. Our Lightning-Link solution is the world’s easiest to use antibody labelling kit, and is employed in hospitals and research labs across the globe. Innova’s relationship with China is of great importance and our two new distributors — 4A Biotech Company and NeoBioscience Technology — will help us penetrate the Chinese market and the significant opportunities it offers.
“As well as appointing new distributors, the last few months has also seen us move into a brand new purpose-built facility at the Babraham Research Campus. Additionally, recent investment in the business has been a vote of confidence in our long-term strategy and will enable us to build on our impressive growth. We will use recent successes as a platform for some exciting new projects that we have in the pipeline,” concluded Dr Gee.
At the core of Innova’s business is the Lightning-Link an innovative technology that simplifies antibody labelling for use in R&D applications, drug discovery and diagnostics. The expanding Lightning-Link portfolio currently consists of 44 individual products and is sold to research laboratories in over 30 countries around the world.